We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+13.24%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.47B
AUM Growth
+$545M
(+28%)
Cap. Flow
-$151M
Cap. Flow
% of AUM
-6.11%
Top 10 Holdings %
Top 10 Hldgs %
69.01%
Holding
41
New
6
Increased
5
Reduced
7
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$54.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$41.8M |
| 3 |
Gilead Sciences
GILD
|
+$28.1M |
| 4 |
Puma Biotechnology
PBYI
|
+$23.7M |
| 5 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$16.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$49.6M |
| 2 |
UAM
Universal American Corp
UAM
|
+$48.5M |
| 3 |
CONMED
CNMD
|
+$33.1M |
| 4 |
ATHN
Athenahealth, Inc.
ATHN
|
+$31.6M |
| 5 |
Perrigo
PRGO
|
+$30.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.49% |
| 2 | Miscellaneous | 31.51% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Option Care Health
OPCH
$3.52B
| $17.3M | 0.7% |
2,545,000
| – | – |
|
27
PTC Therapeutics
PTCT
$5.48B
| $12.3M | 0.5% |
+1,250,000
| New | +$15.1M |
|
|
BIOL
28
DELISTED
Biolase, Inc.
BIOL
| $7.2M | 0.29% |
427
| – | – |
|
|
ARNA
29
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.21M | 0.25% |
425,000
| – | – |
|
30
Atara Biotherapeutics
ATRA
$94.8M
| $2.57M | 0.1% |
+5,000
| New | +$2.07M |
|
|
DXTR
31
DELISTED
Dextera Surgical Inc.
DXTR
| $888K | 0.04% |
837,483
| – | – |
|
|
ATXS
32
DELISTED
Astria Therapeutics
ATXS
| – | – |
-16,667
| Closed | -$3.61M |
|
|
33
Biogen
BIIB
$31.9B
| – | – |
-175,000
| Closed | -$49.6M |
|
34
Centene
CNC
$33.4B
| – | – |
-400,000
| Closed | -$11.3M |
|
|
35
CONMED
CNMD
$1.41B
| – | – |
-750,000
| Closed | -$33.1M |
|
36
PUT
Stryker
SYK
$108B
| – | – |
-1,000,000
| Closed | -$120M |
|
|
AMAG
37
DELISTED
AMAG Pharmaceuticals
AMAG
| – | – |
-611,390
| Closed | -$21.3M |
|
|
ATHN
38
DELISTED
Athenahealth, Inc.
ATHN
| – | – |
-300,000
| Closed | -$31.6M |
|
|
UAM
39
DELISTED
Universal American Corp
UAM
| – | – |
-4,875,000
| Closed | -$48.5M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, Camber Capital Management held 41 positions worth $2.47B, up 28% from $1.92B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Camber Capital Management withdrew a net $151M in Q1 2017, closing 9 positions and reducing 7 holdings. Its most notable exit was Biogen, an estimated $49.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Camber Capital Management opened a new position in Bioverativ Inc. Common Stock worth $59.9M.
- Camber Capital Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 1,100,000 shares worth $59.9M.
- Camber Capital Management added most to Gilead Sciences in Q1 2017, an estimated $28.1M increase.
- Camber Capital Management's biggest Q1 2017 reduction was Perrigo, cutting an estimated $30.4M.
- Camber Capital Management fully exited Biogen in Q1 2017, selling an estimated $49.6M.
- Camber Capital Management's ten largest holdings make up 69% of its $2.47B portfolio in Q1 2017.
- Camber Capital Management opened 6 new positions and closed 9 in Q1 2017.
- Camber Capital Management's portfolio value rose 28% quarter-over-quarter to $2.47B.
Based on Camber Capital Management's 13F filing for Q1 2017, filed 15 May 2017.